200435-89-8

Upstream product

• 350505-61-2 2',3'-O-benzylidene-4'-(p-toluenesulfonyloxymethyl)uridine 
• 25895-60-7 sodium cyanoborohydride 
• 200435-88-7 2',3'-O-benzylidene-4'-(p-toluenesulfonyloxymethyl)uridine 
• 63592-89-2 O^2'_,O3'-cyclohexane-1,1-diyl-4'-hydroxymethyl-uridine 
• 195705-15-8 4'-(p-toluenesulfonyl)oxymethyluridine 
• 98-59-9 p-toluenesulfonyl chloride 
• 195705-07-8 2',3'-O-cyclohexylidene-4'-(p-toluenesulfonyloxymethyl)uridine 

Downstream Products

• 200435-91-2 1-((1S,3R,4R,7S)-7-(benzyloxy)-1-(hydroxymethyl)-2,5-dioxabicyclo[2.2.1]heptan-3-yl)pyrimidine-2,4(1H,3H)-dione 
• 206055-67-6 (1S,3R,4R,7S)-7-hydroxy-1-hydroxymethyl-(thymin-1-yl)-2,5-dioxabicyclo[2.2.1]heptane 
• 206055-71-2 1-[(1R,4R,6R,7S)-4-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptan-6-yl]-5-methylpyrimidine-2,4-dione 
• 206055-75-6 (1R,3R,4R,7S)-3-(thymine-1-yl)-1-(4,4′-dimethoxytrityloxy)-7-(2-cyanoethoxy(diisopropylamino)phosphinoxymethyl)-2,5-dioxabicyclo[2.2.1]heptane 
• 200435-92-3 1-((1S,3R,4R,7S)-7-hydroxy-1-(hydroxymethyl)-2,5-dioxabicyclo[2.2.1]heptan-3-yl)pyrimidine-2,4(1H,3H)-dione 
• 195705-32-9 5'-O-(4,4'-dimethoxytrityl)-2'-O,4'-C-methyleneuridine 
• 206055-76-7 5′-O-(4,4′-dimethoxytrityl)-2′-O,4′-C-methylenethymidine-3′-[O-(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite 
• 200435-95-6 Acetic acid (1R,3R,4R,7S)-1-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-3-(2-oxo-4-[1,2,4]triazol-1-yl-2H-pyrimidin-1-yl)-2,5-dioxa-bicyclo[2.2.1]hept-7-yl ester 
• 200435-94-5 Acetic acid (1R,3R,4R,7S)-1-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-3-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2,5-dioxa-bicyclo[2.2.1]hept-7-yl ester 

Relevant academic research and scientific papers

Bicyclonucleoside and oligonucleotide analogue

An oligo- or polynucleotide analogue having one or more structures of the general formula where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is disclosed. The use of this analogue provides an oligonucleotide analogue antisense molecule, which is minimally hydrolyzable with an enzyme in vivo, has a high sense strand binding ability, and is easily synthesized.

Novel bicyclonucleoside and oligonucleotide analogue

An oligo- or polynucleotide analogue having one or more structures of the general formula where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is disclosed. The use of this analogue provides an oligonucleotide analogue antisense molecule, which is minimally hydrolyzable with an enzyme in vivo, has a high sense strand binding ability, and is easily synthesized.

Bicyclonucleoside and oligonucleotide analogues

An oligo- or polynucleotide analogue having one or more structures of the general formula where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is disclosed. The use of this analogue provides an oligonucleotide analogue antisense molecule, which is minimally hydrolyzable with an enzyme in vivo, has a high sense strand binding ability, and is easily synthesized.

2'-O,4'-C-Methylene bridged nucleic acid (2',4'-BNA): synthesis and triplex-forming properties.

For development of ideal antisense and antigene molecules, various chemical modifications of oligonucleotides have been studied. However, despite their importance, there is only limited information available on the triplex-forming ability of the conformat

Synthesis of 2'-O,4'-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed c3-endo sugar puckering

2'-O,4'-C-Methyleneuridine and -cytidine, novel bicyclic nucleoside analogs having a typical C3'-endo sugar puckering, were synthesized starting from uridine via a several-step sequence.